David S. Hong

TL;DR: Treatment of KRASG 12C-mutant cancer cells with the KRAS(G12C) inhibitor AMG 510 leads to durable response in mice, and anti-tumour activity in patients suggests that AMG510 could be effective in patients for whom treatments are currently lacking.

TL;DR: Sotorasib showed encouraging anticancer activity in patients with heavily pretreated advanced solid tumors harboring the KRAS p.G12C mutation and responded to pharmacokinetics and objective response according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.

TL;DR: MRX34 treatment with dexamethasone premedication was associated with acceptable safety and showed evidence of antitumor activity in a subset of patients with refractory advanced solid tumors.

TL;DR: These data confirm that TRK fusions define a unique molecular subgroup of advanced solid tumours for which larotrectinib is highly active and indicate that long-term administration of larot rectinib are feasible.

TL;DR: Early results in the clinic suggest that this strategy may have a significant salutary impact on diverse tumors, and there is preliminary evidence suggesting that targeting of the IL‐6 system may be beneficial in the treatment of cancer.